LUCA2 and Antibodies That Bind Thereto
The invention provides the identification and characterization of disease and cancer-associated antigen, LUCA2. The invention also provides a family of monoclonal antibodies that bind to antigen LUCA2, methods of diagnosing and treating various human cancers and diseases that express LUCA2.
1 . A method of treating cancer in an individual comprising administering to said individual an amount of a composition sufficient to inhibit the growth of a cancer cell of said cancer in said individual, wherein said composition comprises a substantially purified immunoglobulin polypeptide or an antigen-binding fragment thereof associated with a chemotherapeutic agent, and wherein:
(A) said substantially purified immunoglobulin polypeptide or antigen-binding fragment thereof specifically binds to an epitope that is specifically bound by the anti-LUCA2 antibody produced by the hybridoma having ATCC Deposit No. PTA-5068, wherein said epitope is expressed on normal neutrophils and on LNCaP prostate carcinoma cells; and
(B) said cancer cell is selected from the group consisting of a cancer cell from: an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, a bladder cancer, a bone cancer, a brain or spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumor, a cervical cancer, a chondrosarcoma, a dhordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing's tumor, an extraskeletal myxoid chondrosarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder or bile duct cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck cancer, an islet cell tumor, a Kaposi's Sarcoma, a kidney cancer, a leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine neoplasia, a multiple myeloma, a myelodysplastic syndrome cell, a neuroblastoma, a neuroendocrine tumor, an ovarian cancer, a pancreatic cancer, a papillary thyroid carcinoma, a parathyroid tumor, a pediatric cancer cell, a peripheral nerve sheath tumor, a phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterious unveal melanoma, a rare hematologic disorder, a renal metastatic cancer, a rhabdoid tumor, a rhabdomysarcoma, a sarcoma, a skin cancer, a soft-tissue sarcoma, a squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.
2 . The method of claim 1 , wherein said composition delivers said chemotherapeutic agent to said cancer cell.
3 . The method of claim 2 , wherein said chemotherapeutic agent is delivered into said cancer cell.
4 . The method of claim 1 , wherein said substantially purified immunoglobulin polypeptide is the anti-LUCA2 antibody produced by the hybridoma ATCC No. PTA-5068 or progeny thereof.
5 . The method of claim 1 , wherein said substantially purified immunoglobulin polypeptide is an anti-LUCA2 antibody.
6 . The method of claim 5 , wherein the anti-LUCA2 antibody is a monoclonal antibody expressed by hybridoma ATCC No. PTA# 5068 or by a progeny thereof that produces the anti-LUCA2 antibody produced by hybridoma ATCC Deposit No. PTA-5068.
7 . The method of claim 1 , wherein said substantially purified immunoglobulin polypeptide is an antigen-binding fragment of an anti-LUCA2 antibody.
8 . The method of claim 7 , wherein the anti-LUCA2 antibody is a monoclonal antibody expressed by hybridoma ATCC No. PTA# 5068 or by a progeny thereof that produces the anti-LUCA2 antibody produced by hybridoma ATCC Deposit No. PTA-5068.
9 . The method of claim 1 , wherein said cancer cell is a cancer cell of a breast cancer.
10 . The method of claim 1 , wherein said cancer cell is a cancer cell of a lung cancer.
11 . The method of claim 1 , wherein said cancer cell is a cancer cell of an ovarian cancer.
12 . The method of claim 1 , wherein said cancer cell is a cancer cell of a pancreatic cancer.
13 . The method of claim 1 , wherein said cancer cell is a cancer cell of a colon cancer.
14 . The method of claim 1 , wherein said cancer cell is a cancer cell of a kidney cancer.
15 . The method of claim 1 , wherein said cancer cell is a cancer cell of a prostate cancer.
16 . The method of claim 1 , wherein said cancer cell is a cancer cell of a stomach cancer.
17 . The method of claim 1 , wherein said chemotherapeutic agent is a radioactive molecule.
18 . The method of claim 1 , wherein said chemotherapeutic agent is a cytotoxic agent.